<DOC>
	<DOCNO>NCT02439567</DOCNO>
	<brief_summary>The purpose study evaluate effect sustain virological response liver spleen stiffness patient HCV compensate advanced chronic liver disease treat new oral antiviral drug order determine factor implicate stiffness change implication long-term follow-up .</brief_summary>
	<brief_title>Transient Elastography Assess Liver Fibrosis Portal Hypertension HCV Cirrhotic Patients Treated With New Antiviral Drugs ( SPLEEN-C )</brief_title>
	<detailed_description>Prospective cohort study include consecutive patient ( baseline liver stiffness measurement ≥10 kPa meet Baveno VI criterion compensate advanced chronic liver disease ) initiate treatment new oral antiviral drug follow current recommendation Spain . In patient follow parameter assess : - Baseline liver spleen stiffness CAP measurement time start therapy , treatment week 4 week 12 ( end treatment ) . After finish therapy , measurement repeat 6 12 month follow-up . - Routine lab test , include liver enzymes viral load , perform baseline , 4 12 week therapy , 3 6 month finish therapy accord standard clinical practice . - Liver ultrasound perform every 6 month routine procedure patient wiht liver cirrhosis . - Patients know esophageal varix prior therapy assessed upper endoscopy 12 month finish therapy achieve SVR .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Age 18 90 year . History chronic hepatitis C infection . Compensated advance chronic liver disease ( Baveno VI definition ) : Baseline liver stiffness ≥15 kPa , Baseline liver stiffness 1015 kPa one following : platelet count &lt; 150x10e9/L , spleen size ≥13 cm , nodular liver collateral circulation abdominal ultrasound , HVPG &gt; 5 mmHg , upper gastrointestinal endoscopy show gastroesophageal varix previous liver biopsy show bridge fibrosis cirrhosis . Indication start antiviral treatment new oral drug . Willingness enter study . Sign inform consent . Chronic liver disease due etiology HCV . Terminal illness . Treatment interferon . Liver stiffness measurement &lt; 10 kPa baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Clinically significant portal hypertension</keyword>
	<keyword>Portal hypertension</keyword>
	<keyword>Elastography</keyword>
	<keyword>Antiviral therapy</keyword>
</DOC>